New Bioactive Compound for Difficult-to-Treat Allergies New Bioactive Compound for Difficult-to-Treat Allergies
University of Bonn-guided study leads to the discovery of a promising receptor blocker
Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in common that they are triggered by an excessive immune response—which in severe cases can be life-threatening. A team of researchers led by the University of Bonn has now identified a promising bioactive compound that could effectively reduce symptoms and slash fatality risk. The compound blocks a receptor on certain defense cells, thus preventing a derailed immune response. The study findings have been published in the journal Signal Transduction and Targeted Therapy.

Ghazl Al Hamwi et. al.: Subnanomolar MAS-related G protein-coupled receptor-X2/B2 (MRGPRX2/B2) antagonists with efficacy in human mast cells and disease models; Signal Transduction and Targeted Therapy; DOI: 10.1038/s41392-025-02209-82
Links
- https://www.uni-bonn.de/en/news/072-2025
- https://doi.org/10.1038/s41392-025-02209-8